Share:
- Committee reviewed clinical data showing a favorable safety profile and high vaccine efficacy of 90.7% in children 5 to <12 years of age during a period when Delta was the prevalent strain
- 10-µg dose level used in the trial for children 5 to <12 years of age was carefully selected based on safety, tolerability and immunogenicity data
- If Emergency Use Authorization is granted, the Pfizer-BioNTech COVID-19 Vaccine will be the first COVID-19 vaccine authorized in the U.S. for use in this age group
Read the full press release here.
Source : Pfizer Inc.
Related HIV and Co-Infections News
-
Infectious Disease Advisor: Breakthrough COVID-19 does not meaningfully affect HIV CD4+ count
-
[Press release] Shionogi announces FDA approval of XOCOVA® (ensitrelvir), the first and only oral option to help prevent COVID-19 following exposure
-
[CROI 2026] HIV i-Base: Nine comprehensive free reviews in Topics in Antiviral Medicine
Get involved
Are you living with HIV/AIDS? Are you part of a community affected by HIV/AIDS and co-infections? Do you work or volunteer in the field? Are you motivated by our cause and interested to support our work?
Subscribe
Stay in the loop and get all the important EATG updates in your inbox with the EATG newsletter. The HIV & co-infections bulletin is your source of handpicked news from the field arriving regularly to your inbox.